Instil Bio Inc TIL.OQ TIL.O is expected to show no change in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Instil Bio Inc is for a loss of $2.35 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Instil Bio Inc is $88.00, about 82.9% above its last closing price of $15.02
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -2.92 | -2.50 | -3.24 | Missed | -29.5 |
Mar. 31 2025 | -2.74 | -2.59 | -4.32 | Missed | -67 |
Dec. 31 2024 | -3.26 | -3.22 | -1.82 | Beat | 43.5 |
Sep. 30 2024 | -2.33 | -2.11 | -3.54 | Missed | -68 |
Jun. 30 2024 | -2.99 | -2.98 | -2.29 | Beat | 23.2 |
Mar. 31 2024 | -2.22 | -2.23 | -3.74 | Missed | -67.7 |
Dec. 31 2023 | -2.29 | -2.84 | -1.99 | Beat | 30.1 |
Sep. 30 2023 | -1.98 | -2.00 | -10.40 | Missed | -420 |
This summary was machine generated November 7 at 16:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)